HSM Helius Medical Technologies Inc

Advocates Reveal State of Progress, Need for More Clinical Research During Brain Injury Awareness Month

As the nation kicks off March as Brain Injury Awareness Month, leading advocates acknowledge accomplishments and advances in the field but recognize further advances are needed to help the more than five million people living with brain injuries in the U.S. today. Patient advocate and television personality Montel Williams and the Brain Injury Association of America (BIAA) have once again joined forces to call for greater strides in awareness, understanding, access to quality care, treatment opportunities and research for concussion and traumatic brain injury (TBI).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170301006186/en/

Brain Injury Awareness Month - TBI By the Numbers

Brain Injury Awareness Month - TBI By the Numbers

In advance of Brain Injury Awareness Month, Montel Williams and Helius Medical Technologies, in partnership with BIAA, launched Tackling TBI,” an awareness campaign for TBI. The mission of the campaign is to raise awareness of TBI and concussions as growing health issues, to educate patients and caregivers, provide resources and to share opportunities to participate in research. The campaign includes a Public Service Announcement (PSA) featuring Montel Williams and former NFL player Marvin Washington, and a video series of interviews with TBI patients. Information on a Helius sponsored clinical trial for TBI can be found at www.braininjurytrial.com.

“Currently more than 5.3 million Americans in the U.S. live with a lifelong disability as a result of a TBI and there are 1.7 million new cases each year,” said Montel Williams. “But this isn’t just a civilian issue, an average of 15,000 active duty service members acquire brain injuries every year. Our goal is to raise awareness and provide patients information about new therapies in clinical trials so that they can have an educated discussion with their healthcare provider about the best option for them. My goal is to apply what I’ve learned as an MS patient and help those suffering from TBI become educated participants in their own courses of treatment.”

“Brain injury has been thrust onto the national circuit as a result of important discussions around football players and veterans and now there remains important work to be done for all Americans living with the condition,” said Susan Connors, president and chief executive officer of BIAA. “A TBI can be the start of a misdiagnosed and misunderstood neurological disease and we need to expand on how we deliver help, hope and healing to the millions who have sustained this life-altering, sometimes devastating, injury.”

Recent brain injury advances include:

  • A three-year project to develop first-time Guidelines for the Rehabilitation and Disease Management of Adults with Moderate to Severe Traumatic Brain Injury.
  • The recent passing of the 21st Century Cures Act that will allow for the establishment of an NIH data collection system to track the incidence and prevalence of neurological conditions, provide NIH and FDA with new funding for medical research and new treatments, and support the coordination and collaboration of rehabilitation research.
  • Public awareness including BIAA’s Not Alone campaign designed to educate the general public about the incidence of brain injury and the needs of people with brain injuries and their families. The campaign works to de-stigmatize the injury, empower those who have survived, and promote the many types of support that are available.
  • The availability of clinical trials to support the development of new therapies.

A TBI is an injury that disrupts the normal function of the brain and can be caused by a host of things such as sports, car accidents, military service, trips, slips or falls. For many people, TBI causes fatigue, headaches, and difficulty with balance or motor skills, slurred speech, or seizures. Depending on the severity of the brain injury sustained, individuals with brain injuries need an array of emergency services, hospitalization, physician services, and medications to survive injury, as well as a continuum of treatments and rehabilitation to recover and regain as much lost function as possible over time.

About the Brain Injury Association of American (BIAA)

The Brain Injury Association of America is the country’s oldest and largest nationwide brain injury advocacy organization. BIAA’s mission is to advance awareness, research, treatment, and education and to improve the quality of life for all people affected by brain injury. BIAA is dedicated to increasing access to quality health care and raising awareness and understanding of brain injury. Further resources and information related to brain injury are available at http://www.BIAUSA.org, BIAA on Facebook and Twitter Page and through the National Brain Injury Information Center (NBIIC) at 1-800-444-6443.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. For more information, please visit www.heliusmedical.com.

To download media resources for the “Tackling TBI” campaign visit: www.tacklingtbi.com.

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory approvals, business initiatives and objectives and use of proceeds from financings or other business initiatives.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure of the Company to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, including the short form prospectus filed in connection with the Offering, its Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.

EN
01/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Helius Medical Technologies Inc

 PRESS RELEASE

Helius Announces Positive Outcome of the Portable Neuromodulation Stim...

Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance defi...

 PRESS RELEASE

Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Li...

Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Ru...

 PRESS RELEASE

Helius Medical Technologies Announces Reverse Stock Split

Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company’s common stock will trade on The Nasdaq Capital Market on a split adjusted basis. At the Company’...

 PRESS RELEASE

Helius Medical Technologies, Inc. Announces Claim Authorization by Cig...

Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device - CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neu...

 PRESS RELEASE

Positive PoNSTEP Study Results Presented at Consortium of Multiple Scl...

Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting -PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch